Diana Arsene, MD
Gastroenterology · Colorado Springs, CONPI 1679830871
Payments from drug & device makers
What this record shows
This record is dominated by grants: $36,838 of the $38,664 with a category attached, or 95.3%. Pfizer accounts for 95.8% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $36,943 and has fallen 99.4% since, to $230 in 2025. Among gastroenterology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $402.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$37K
- AbbVie$427
- Takeda Pharmaceuticals U.S.A., Inc.$181
- Bristol Myers Squibb$168
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$137
- Johnson & Johnson$135
- plus $592 from 17 others
Across 5 payments — averaging $4400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$22K
What the payments were for
- Grants$36,83895%
- Food & beverage$1,8005%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 13 | $37,024 |
| AbbVie | 22 | $427 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $181 |
| Bristol Myers Squibb | 9 | $168 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $137 |
| Johnson & Johnson | 8 | $135 |
| Ardelyx, Inc. | 5 | $132 |
| Lilly USA, LLC | 3 | $92 |
| Madrigal Pharmaceuticals | 2 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Nestle Healthcare Nutrition Inc. | 2 | $36 |
| Celltrion USA Inc. | 2 | $36 |
| Intercept Pharmaceuticals, Inc. | 2 | $33 |
| Sanofi | 1 | $23 |
| Merck | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $15 |
| QOL Medical, LLC | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
How this compares
$38,664 in reported general payments places this provider in the 90th percentile of 304 gastroenterology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 22 | $808,716 |
| Humira(Cf) PenAdalimumab | 14 | $176,388 |
| XifaxanRifaximin | 15 | $53,061 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 27 | $4,397 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 31 | $3,892 |
| Sucralfate | 16 | $3,581 |
| Mesalamine ErMesalamine | 12 | $2,020 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 61 | $1,427 |
| Esomeprazole Magnesium | 12 | $1,373 |
| Omeprazole | 55 | $1,297 |
| Pantoprazole Sodium | 69 | $972 |
| Lactated RingersRinger's Solution,lactated | 37 | $668 |
| Dicyclomine Hcl | 12 | $383 |
| Famotidine | 20 | $351 |
| Lactulose | 14 | $211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $135 | $808,71622 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $137 | $53,06115 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $15 | $8,28958 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 304 gastroenterology providers in Colorado.
Other gastroenterology in Colorado Springs
- Douglas AdlerColorado Springs$910K
- Bhaktasharan PatelColorado Springs$30K
- Lukasz KowalczykColorado Springs$25K
- Thomas MeisterColorado Springs$17K
- Peter McNallyFt Carson$1.1M
- Marcelo KugelmasEnglewood$660K
- Mary Ann HuangDenver$408K
- Gareth WeinerThornton$382K
- Matthew NicholsLone Tree$360K
- Nathan SchomakerLone Tree$344K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.